Login to Your Account

CancerVax’s Second Round Raises $55M For Canvaxin

By Kim Coghill

Friday, April 5, 2002
CancerVax Corp., a young company studying a vaccine for melanoma and colon cancer, on Monday said it raised $55 million in its second round of financing through the private placement of preferred stock. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription